LONG-TERM MUTATIONAL DYNAMICS IN DEL(5Q) MDS PATIENTS EARLY TREATED WTIH LENALIDOMIDE (SINTRAREV CLINICALTRIAL). SAFE AND EFFECITIVE APPROACH REGARDING CLONAL EVOLUTION?
Leuk Res
2023
128 Suppl S
Pembrolizumab and trastuzumab in combination with FLOT in the perioperative treatment of HER2-positive, localized esophagogastric adenocarcinoma-a phase II trial of the AIO study group (AIO STO 0321).
Front Oncol
2023
13
S-1 maintenance therapy in Caucasian patients with metastatic esophagogastric adenocarcinoma-final results of the randomized AIO MATEO phase II trial.
ESMO Open
2023
8
3
Applicability of the new WHO Classification for the MDS: Data from the Dusseldorf MDS Registry
Oncology Research and Treatment
2023
46 Suppl 5
205-205
VENETOCLAX AND HYPOMETHYLATING AGENTS FOLLOWED BY ALLOGENEIC STEM CELL TRANSPLANTATION IN PATIENTS WITH ACUTE MYELOID LEUKEMIA
Bone Marrow Transplant
2023
58 Suppl 1
SUPP1
163-163
Development of Highly Sensitive Digital Droplet PCR for Detection of cKIT Mutations in Circulating Free DNA That Mediate Resistance to TKI Treatment for Gastrointestinal Stromal Tumor (GIST).
Int J Mol Sci
2023
24
6
A ROLE FOR ANTIGEN PRESENTATION PROCESSES IN MDS/AML RELAPSE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION UNCOVERED BY SINGLE CELL TRANSCRIPTOMIC ANALYSIS OF THE BONE MARROW MICROENVIRONMENT
Ann Hematol
2023
102 Suppl 1
SUPPL 1
S23-S23
Expression-linked and R-ISS-Adapted Stratification for first line therapy in multiple myeloma patients (ELIAS)
Oncology Research and Treatment
2023
46 Suppl 5
182-183
Patient-tailored adoptive immunotherapy with EBV-specific T cells from related and unrelated donors.
J Clin Invest
2023
133
12
Allogeneic hematopoietic cell transplantation in patients with CALR-mutated myelofibrosis: a study of the Chronic Malignancies Working Party of EBMT.
Bone Marrow Transplant
2023
58
12
1357-1367